

SUPPLEMENTARY DATA

Supplementary Table S1. Characteristics of the Older Adults with Diabetes*

Characteristic	Overall*	65-75 years old	>75 years old
	Number (%)	Number (%)	Number (%)
Total	303,097 (100)	176,805 (58.3)	126,292 (41.7)
Sex			
Male	299,249 (98.7)	174,342 (98.6)	124,907 (98.9)
Female	3,848 (1.3)	2,463 (1.4)	1,385 (1.1)
Anti-glycemic agents			
Other than Insulin or Sulfonylureas	5,506 (1.8)	2,812 (1.6)	2,694 (2.1)
Sulfonylureas only	53,092 (17.5)	22,167 (12.5)	30,925 (24.5)
Sulfonylureas and Metformin only	55,999 (18.5)	36,191 (20.5)	19,808 (15.7)
Sulfonylureas and other (not Insulin)	12,619 (4.2)	7,577 (4.3)	5,042 (4.0)
Insulin only	91,319 (30.1)	50,029 (28.3)	41,290 (32.7)
Insulin and Metformin only	36,878 (12.2)	27,695 (15.7)	9,183 (7.3)
Insulin and Sulfonylureas only	21,013 (7.0)	10,797 (6.1)	10,216 (8.1)
Insulin and Sulfonylureas and Metformin only	19,294 (6.4)	14,562 (8.2)	4,732 (3.8)
Insulin and other	7,377(2.4)	4,975 (2.8)	2,402 (1.9)
Serum creatinine (mg/dl)			
not available	39,405 (13.0)	21,508 (12.2)	17,897 (14.2)
<1.7	228,467 (75.4)	138,902 (78.6)	89,565 (70.9)
1.7-<2.0	17,114 (5.6)	7,490 (4.2)	9,624 (7.6)
2.0-<2.5	9,574 (3.2)	4,156 (2.4)	5,418 (4.3)
2.5-<3.0	3,209 (1.1)	1,499 (0.8)	1,710 (1.4)
>=3.0	5,328 (1.8)	3,250 (1.8)	2,078 (1.6)
Coexisting co-morbid conditions			
Presence of >=1 co-morbid condition	193,689 (63.9)	106,866(60.4)	86,823 (68.7)
Serum creatnine >=1.7 mg/dl	35,225 (11.6)	16,395 (9.3)	18,830 (14.9)
Diminished Life Expectancy [†]	39,282 (13.0)	20,410 (11.5)	18,872 (15.0)
Cancer	38,520 (12.7)	19,772 (11.2)	18,748 (14.9)
Advanced Diabetic Complications [‡]	29,896 (9.9)	16,063 (9.1)	13,833 (11.0)
Advanced retinopathy	29,177 (9.7)	15,548 (8.9)	13,629 (10.8)
Cognitive impairment or Dementia	23,981 (7.9)	9,451 (5.4)	14,530 (11.5)
Other Neurological Conditions [§]	12,459 (4.1)	6,727 (3.8)	5,732 (4.6)
Cardio-vascular diseases	127,565 (42.1)	68,777 (39.0)	58,788 (46.6)
Myocardial infarction	7,763 (2.6)	4,540 (2.6)	3,223 (2.6)
Chronic heart failure	30,967 (10.2)	16,034 (9.1)	14,933 (11.7)
Ischemic vascular disease	116,721 (38.6)	63,176 (35.8)	53,545 (42.5)
Major depression	14,317 (4.7)	11,659 (6.6)	2,658 (2.1)
Alcohol/substance abuse	9,497 (3.2)	8,278 (4.7)	1,219 (1.0)
Glycemic control			
HbA1c, mean±SD, %	7.6±1.4	7.7±1.4	7.4±1.2
<6.5	(60 ±15.3mmol/mol) 55,705 (18.4)	(61 ±15.3mmol/mol) 29,668 (16.8)	(57 ±13.1mmol/mol) 26,037 (20.6)

SUPPLEMENTARY DATA

6.5 - <7.0	53,248 (17.3)	28,773 (16.3)	23,575 (18.7)
7.0 - 7.4	55,587 (18.2)	31,401 (17.7)	24,186 (19.1)
7.5 - 8.5	84,398 (27.8)	50,185 (28.4)	34,213 (27.1)
8.6 - 9.0	19,782 (6.5)	12,531 (7.1)	7,251 (5.8)
>9	35,277 (11.7)	24,247 (13.8)	11,030 (8.7)
[<7	108,053 (35.7)	58,441 (33.1)	49,612 (39.3)
<8	209,896 (69.3)	116,917 (66.1)	92,979 (73.6)]

Abbreviation: HbA1c, hemoglobin A1c.

SI conversion factors: To convert serum creatinine to micromoles per liter multiply by 88.4;

* includes patients, aged 65+, with HbA1c value available in fiscal year (FY) 2013, who were receiving any anti-glycemic medications, except Metformin-only prior last HbA1c in FY 2013.

[†] Diminished Life Expectancy includes end-stage hepatic disease and cancer (excluding basal and squamous skin cancers).

[‡] Advanced Diabetic Complications includes end-stage renal disease, amputation, and advanced retinopathy.

[§] Other Neurological Conditions includes gastroparesis, Parkinson disease, aphasia, dysphasia, hemiplegia, apraxia, epilepsy, transient ischemic attack.

^{||} Patient may have more than one cardio-vascular condition. Subcategories are not mutually exclusive.